The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience.

BACKGROUND: Rituximab, a monoclonal antibody directed against CD20, is approved for the treatment of CD20-positive B-cell Non-Hodgkin's lymphoma and rheumatologic disorders. Due to its potent activity in depleting CD20-positive lymphocytes, the influence on opportunistic infections is still under discussion. Thus, we analyzed the impact of rituximab either as monotherapy or in combination with other chemotherapeutic regimens to elucidate its role in contributing to infectious complications. METHODS: The records of consecutive patients (n = 125, 141 treatment episodes) treated with rituximab alone or in combination with chemotherapy and corticosteroids were analyzed retrospectively for the incidence, spectrum and outcome of infections during treatment and 6 months after the last course of rituximab. Univariate analysis of cofactors such as steroid medication, antiinfective prophylaxis, underlying disease and remission status were performed. RESULTS: Altogether 80 therapy episodes were associated with infections, the median number of infections per patient being 1 (range 1-7). The number of infectious complications was significantly higher in patients receiving a combination of rituximab and chemotherapy compared to rituximab monotherapy (p < 0.001). There was no statistically significant difference regarding number of rituximab courses or cumulative rituximab dosage between episodes with and without infections, respectively.Mean cumulative prednisone dosage between the cohort with infections and the one without infections showed a trend towards higher dosage of prednisone in the patients with infections (mean difference 441 mg, p > 0.14). CONCLUSIONS: Rituximab in induction treatment, either as monotherapy or combined with chemotherapy by itself does not increase the incidence or change the spectrum of infections in hematologic patients. However the possible influence of higher dosages of concomitant steroid medication on frequency of infections suggests that a heightened awareness of the potential for infectious complications should be applied to patients receiving higher doses of glucocorticoids in combination with other therapeutic regimens.

[Blood oxygenation level dependent (BOLD)--renal imaging: concepts and applications]. / Blood oxygenation level dependent (BOLD)--Bildgebung der Nieren: Konzepte und Anwendungen.

Many renal diseases as well as several pharmacons cause a change in renal blood flow and/or renal oxygenation. The blood oxygenation level dependent (BOLD) imaging takes advantage of local field inhomogeneities and is based on a T2*-weighted sequence. BOLD is a non-invasive method allowing an estimation of the renal, particularly the medullary oxygenation, and an indirect measurement of blood flow without administration of contrast agents. Thus, effects of different drugs on the kidney and various renal diseases can be controlled and observed. This work will provide an overview of the studies carried out so far and identify ways how BOLD can be used in clinical studies.

Susceptibility weighted imaging (SWI) of the kidney at 3T--initial results.

Susceptibility weighted imaging provides diagnostic information in strokes, hemorrhages, and cerebral tumors and has proven to be a valuable tool in imaging venous vessels in the cerebrum. The SWI principle is based on the weighting of T(2)* weighted magnitude images with a phase mask, therewith improving image contrast of veins or neighbouring structures of different susceptibility, in general. T(2)* weighted MRI is already used for assessment of kidney function. In this paper, the feasibility of SWI on kidneys was investigated. Translation of SWI from the brain to the kidneys comes along with two main challenges: (i) organ motion due to breathing and (ii) a higher oxygenation level of renal veins compared to the brain. To handle these problems, the acquisition time has been cut down to allow for breath-hold examinations, and different post-processing methods including a new phase mask were investigated to visualize renal veins. Results showed that by a new post-processing strategy SWI contrast was enhanced on average by a factor of 1.33 compared to the standard phase mask. In summary, initial experiences of SWI on the kidneys demonstrated the feasibility. However, further technical developments have to be performed to make this technology applicable in clinical abdominal MRI.

Thoracic and abdominal MRA with gadofosveset: influence of injection rate on vessel signal and image quality.

The purpose of this study was to investigate the influence of different injection rates on the maximum signal intensity and the arterio-venous transit time of dynamic gadofosveset-enhanced first pass MR angiography (MRA). Twenty-one healthy male volunteers were examined with a time-resolved echo-shared MRA at 1.5 T. The volunteers were assigned into three groups using injection rates of either 1, 2 or 4 ml/s. The maximal signal enhancement and peak signal-to-noise ratio in the pulmonary trunk, the aortic arch, the abdominal aorta as well as both kidneys and lung parenchyma were analyzed. The arterio-venous transit time was determined. The time between maximal enhancement of the pulmonary trunk and the aortic arch was higher with the slow injection rate of 1 ml/s, while there were no differences in the time between maximal enhancement of the aortic arch and the abdominal aorta above or below the origin of the renal veins with all three injection rates. With the slow injection protocol of 1 ml/s a longer purely arterial phase of 10.5 s was achieved compared to 7.7 s with higher injection rates (p = 0.045). The time between maximal aortic signal intensity and maximal renal enhancement was equal for all injection protocols.